TriSalus 10-Q: Q3 Revenue $12.9M, Net Loss Narrows to $8.9M, $41.1M Cash
TLSI sits 36% above its 52-week low of $2.2.
Summary
TriSalus' Q3 10-Q shows revenue up 11.3% to $12.9 million with 86.2% gross margin, an $8.9 million net loss, and $41.1 million of cash — but a still-unremediated material weakness and a sixth OrbiMed covenant amendment.
Key Events · Earnings and Guidance · TLSI
-
Q3 Revenue $12.9M, Up 11.3%
Revenue rose to $12.9 million from $11.6 million a year earlier, with gross margin improving to 86.2% from 83.5% on lower cost per TriNav unit.
-
Net Loss Narrows to $8.9M
Q3 net loss was $8.9 million versus $10.8 million a year earlier; the nine-month loss fell to $16.5 million from $29.5 million, helped by $5.8 million and $7.1 million of non-cash fair-value gains on warrant and earnout liabilities.
-
Sales Spend Up 56.9%, R&D Down 44.1%
Sales and marketing expense rose to $10.7 million from $6.8 million while R&D fell to $3.2 million from $5.7 million as nelitolimod trial costs did not recur.
-
Cash $41.1M After $42.6M Raise
Cash and equivalents stood at $41.1 million at September 30, 2026 versus $20.4 million at December 31, 2025, following $42.6 million of net proceeds from the February 2026 equity offering.
Analysis · TLSI · Industrial Applications And Services
The 10-Q fills in the numbers behind this morning's 8-K. Revenue grew 11.3% to $12.9 million and gross margin improved to 86.2%, but that growth is being bought: sales and marketing expense jumped 56.9% to $10.7 million in the quarter, which is why full-year guidance was trimmed to $46-48 million. The balance sheet is the reassuring part — $41.1 million of cash after February's $42.6 million equity raise, against $32.4 million of OrbiMed term debt that does not begin amortizing while TriNav revenue clears the amended thresholds. Two items carry real weight: the material weakness in internal controls over significant-transaction accounting is still unremediated, and the company keeps leaning on OrbiMed amendments (the sixth, signed September 29, 2026, lowered three revenue thresholds for a $1.09 million fee) to stay ahead of the repayment trigger. Net loss of $8.9 million for the quarter was flattered by $0.7 million of non-cash gains on warrant and earnout remeasurement — mark-to-market entries driven by the share price, not cash or new dilution.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLSI was trading at $3.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $198.3M. The 52-week trading range was $2.20 to $7.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.